Trials in the Key of G: Building Level 1 Evidence on the Real-world Effectiveness of Prostate Biomarkers

Linda A Okoth; Anna C Harris; Udit Singhal; Michael L Cher; Daniel E Spratt; Todd M Morgan

doi:10.1016/j.euf.2022.08.001

Trials in the Key of G: Building Level 1 Evidence on the Real-world Effectiveness of Prostate Biomarkers

Eur Urol Focus. 2022 Jul;8(4):897-900. doi: 10.1016/j.euf.2022.08.001. Epub 2022 Aug 10.

Authors

Linda A Okoth¹, Anna C Harris¹, Udit Singhal², Michael L Cher³, Daniel E Spratt⁴, Todd M Morgan⁵

Affiliations

¹ Department of Urology, University of Michigan, Ann Arbor, MI, USA.
² Department of Urology, University of Michigan, Ann Arbor, MI, USA; Department of Urology, Mayo Clinic, Rochester, MN, USA.
³ Department of Urology, Wayne State University, Detroit, MI, USA.
⁴ University Hospitals Seidman Cancer Center, Case Western Reserve, Cleveland, OH, USA.
⁵ Department of Urology, University of Michigan, Ann Arbor, MI, USA. Electronic address: tomorgan@umich.edu.

Abstract

A number of genomic classifiers are available to aid in shared decision-making for men with localized prostate cancer; however, there is no high-level evidence assessing their clinical utility. The two randomized controlled trials in this report prospectively evaluate the use of gene expression classifier testing at the time of cancer diagnosis and after surgical treatment.

Publication types

Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural

MeSH terms

Genomics
Humans
Male
Prostate*
Prostate-Specific Antigen
Prostatic Neoplasms* / diagnosis
Prostatic Neoplasms* / genetics
Prostatic Neoplasms* / surgery

Substances

Prostate-Specific Antigen

Abstract

Publication types

MeSH terms

Substances

Grants and funding